To investigate the clinical significance of MCM3 in human prostate cancer progression, immunohistochemical analysis was performed on normal human prostate, benign prostatic hyperplasia, primary prostate cancer, and human bone metastatic prostate cancer tissues (Figures 2D and 3). Here, MCM3 is linked to benign prostatic hyperplasia.